Revance's Botox Rival Receives USFDA Nod

By Indu Tyagi Ketan , 19 October, 2022

DaxibotulinumtoxinA (Daxxify), Revance's long-awaited Botox rival, has officially received FDA approval, as the company is now gearing up to establish its brand. Daxxify is an intravenous neuromodulator similar to Botox; its novel peptide exchange technology temporarily eases the moderate to severe glabellar (frown) lines. 

The trials revealed that a single injection had a significant anti-wrinkle impact on durational effects were proven in phase 3 trials with 4,200 treatments and 2,700 patients. The chief differentiator for Daxxify is its endurance; it can last six months and has even proven effective for up to nine months in some individuals, vis-a-vis Botox injections that last only for three months.

Daxxify was initially scheduled to receive FDA approval in November 2020, but the epidemic slowed inspection. After visiting Revance's production facility, inspectors discovered quality control and record-keeping issues. The FDA then issued Revance a detailed response letter in October of last year. Soon after,  the FDA approved the changes in July after Revance resolved all five problems mentioned in the Complete Response Letter. 

In a separate report, Goldman Sachs predicted that Revance's Daxxify will cost about 30% more than its competitors, even though pricing has not yet been made public. This cost considers the extended value proposition for both doctors and patients. Revance's stock rose 18% in September post the FDA's approval, which is expected to end Botox's long-standing dominance in the aesthetics industry.

USFDA-Approves-DAXXIFY

Latest News

USFDA-Approves-DAXXIFY
Climate Change Responsible For Reducing Fossil Fuels Efficiency In Electricity Production

The climate change issue is necessary since the global clean energy transition has emerged. Green energy transformation requires specific environmental changes strictly followed by the industrial sectors. However, global warming can reduce the…

Read More

USFDA-Approves-DAXXIFY
New Face Of Lithium-Sulfur Batteries For The Low-Cost Batteries In 2024

Solid-state batteries have not been in use for a long time. However, the rising demand for electric vehicles in the automotive market may revamp the sulfur content of solid-state batteries. There are many advantages of sulfur in solid-state…

Read More

USFDA-Approves-DAXXIFY
Microsoft To Invest USD 3.4 Billion On Artificial Intelligence In Germany

Artificial intelligence is enhancing the tech industry nowadays. In the past years, artificial intelligence has played a pivotal role in functioning cloud computing and other tech industry infrastructure. One of the bug techs, Microsoft, is investing…

Read More

USFDA-Approves-DAXXIFY
Solar And Wind Energy Leads to Environmental Waste in 2024

Renewable energy is considered as an alternative to fossil fuels. Nations are replacing fossil fuels with renewables to achieve sustainability in the environment. Renewable energy sources regulate specific sectors like electricity, transportation…

Read More

USFDA-Approves-DAXXIFY
Sustainable Aviation Fuel From Human Waste Can Accelerate Clean Energy Transition

In the industrial applications and production sector, sustainability will play a significant role in  2024. Industries are growing interested in adopting sustainable approaches in light of the clean energy transition. The aviation industry in 2024…

Read More

Author Pic
Indu Tyagi Ketan

Chief Strategy Officer